HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Read more about HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL.
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Read more about Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. Read more about Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.
Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms. Read more about Genetically defined individual reference ranges for tryptase limit unnecessary procedures and unmask myeloid neoplasms.
Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL Read more about Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL
Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Read more about Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium.
The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry. Read more about The impact of in utero transfusions on perinatal outcomes in patients with alpha thalassemia major: the UCSF registry.
Adapting a patient-centered communication tool for older patients with acute myeloid leukemia and their oncologist. Read more about Adapting a patient-centered communication tool for older patients with acute myeloid leukemia and their oncologist.
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Read more about Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant. Read more about Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.
